EstroGel ®
We recently decided to stop copromoting EstroGel®, effective as of September 1, 2016, in order to concentrate our promotional efforts on other product that we promote.
Zoptrex
We expect to complete the ZoptEC trial in 2016 and, if the results of the trial warrant doing so, to file the New Drug Application ("NDA") for Zoptrex™ in 2017, looking toward commercial launch of the product in 2018, assuming positive Phase 3 results and that our NDA is granted.
.Dann warten wir mal ein wenig länger!
Macrilen™
We will focus on finalizing patient recruitment for the confirmatory Phase 3 trial in AGHD. We currently estimate that the trials will be completed by year end, with expected combined third party expenses of approximately $1.9 million over the remaining trial period, including report writing. This would permit us to submit a NDA for Macrilen™ to the FDA in the first half of 2017 and, if the study is successful in meeting its primary endpoint, to obtain FDA approval of the drug by theend of 2017
Outstanding Share Data
As at August 9, 2016, we had 9,939,863 common shares issued and outstanding, as well as 328,299 stock options outstanding. Warrants outstanding as at August 9, 2016 represented a total of 2,842,309 equivalent common shares (excluding any exercises of Series B Warrants under the alternate cashless exercise feature of such warrants)
(Serie-B derzeit ~460T Aktien)
Between April 1, 2016 and June 30, 2016, the Company issued a total of 11,166 common shares under the April 2016 ATM Program at an average price of approximately $4.25 per share for aggregate gross proceeds of approximately $47,300 less cash transaction costs of $1,700 and previously deferred transaction costs of $1,700. In connection with these issuances and in accordance with their respective anti-dilution provisions, the exercise price of the March 2015 Series A and Series B warrants was adjusted to $4.23
Ich gehe davon aus, das die Serie-B noch ausgeübt wird bevor sie im September ausläuft.
Das könnte sich noch als Turbulenzen im Kurs, aber unwesentlich in der Verdünnung auswirken!
Liquidity, Cash Flows and Capital Resources
While the Company has $26.2 million of cash and cash equivalents, we believe that our cash and cash resources will not be sufficient to fund operations for the next twelve months unless our expenditures are reduced or further financing is obtained. Our ability to continue as a going concern is dependent upon raising additional financing through equity and non dilutive funding :-) and partnerships.
http://ir.aezsinc.com/sites/.../files/doc_library/file/Q2-2016-FS.pdf
http://ir.aezsinc.com/sites/...files/doc_library/file/Q2-2016-MDA.pdf
|
Thread abonnieren
